Nelpa Lifesciences Inc Pharmaceutical Import Profile — Philippines (DGFT 2022–2026)

Name: Nelpa Lifesciences Inc Pharmaceutical Import Records from India — 11 Products, $13.3M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Nelpa Lifesciences Inc — Pharmaceutical Importer Profile (2026) | 11 Products, $13.3M Trade | TransData Nexus

Nelpa Lifesciences Inc

Pharmaceutical Importer · Philippines · Cardiovascular Focus · $13.3M Total Trade · DGFT Verified

Nelpa Lifesciences Inc is a pharmaceutical importer based in Philippines with a total trade value of $13.3M across 11 products in 7 therapeutic categories. Based on 284 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Nelpa Lifesciences Inc sources from 12 verified Indian suppliers, with Bdh Healthcare Private Limited accounting for 20.8% of imports.

Nelpa Lifesciences Inc — Import Portfolio & Supplier Network

Nelpa Lifesciences Inc import network — 11 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Nelpa Lifesciences Inc?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Bdh Healthcare Private Limited	$4.7M	388	20.8%
Bdh Industries Limited	$4.7M	278	20.8%
Vins International Private Limited	$3.0M

What Formulations Does Nelpa Lifesciences Inc Import?

Formulation	Value	Ships
Pharmaceutical products- pipetasaph-4.5GM (piperacillin 4g+tazobactam 500MG powder for injection USP	$271.1K	16
Megyxan 500 (mefenamic acid 500 MG	$201.8K	10
Pharmaceutical products moxeth amoxicillin capsule BP 500 MG	$200.0K	4
Pharmaceutical products-saphormin t	$158.9K	9
Pharmaceutical products- saphormin t	$156.1K	7
Pharmaceutical products-harmless medicine-saphmox 500 capsule amoxicillin BP 500 MG capsules ( 100860 1010c)	$150.0K	3
Pharmaceutical products-harmless medicine for human consumption saphteride-5 (finasteride tablets USP 5 MG)	$143.1K	3
Pharmaceutical products- merosaph 1000 (meropenem (as trihydrate) for injectionusp 1000	$141.0K	3
Saphlopid(clopidogrel tablets usp75 MG)	$131.0K	4
Saphroxen 550 (naproxen sodium tablets	$124.5K	4
Pharmaceutical products harmless medicine, saphlor-50 (losartan potassium tablets USP 50MG)	$121.7K	7
Saphlecox 200 celecoxib capsule. 200	$115.9K	6
Pharmaceutical products- saphlecox 200	$114.5K	4
Pharmaceutical products harmless medicine-cloxasaph 500 (cloxacillin 500 MG capsules) ( 150401010c)	$109.7K	3
Pharmaceutical products-merosaph 1000	$100.0K	2

Nelpa Lifesciences Inc imports 1,053 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 11 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Losartan	Cardiovascular	$4.2M	83	1.4%	3
2	Celecoxib	Analgesics & Antipyretics	$3.4M	68	2.5%	3
3	Potassium	Nutritional Supplements	$2.3M	45	0.4%	8
4	Vitamin	Nutritional Supplements	$900.0K	18	0.6%	5
5	Zinc	Vitamins & Supplements	$800.0K	16	1.0%	7
6	Amino	Nutritional Supplements	$600.0K	12	0.2%	10
7	Erythromycin	Antibiotics	$450.0K	9	0.6%	2
8	Colchicine	Lipid & Metabolism	$251.6K	12	1.2%	12
9	Clindamycin	Antibiotics	$200.0K	4	0.2%	13
10	Ambroxol	Respiratory & OTC	$170.2K	14	1.2%	11
11	Folic	Nutritional Supplements	$150.0K	3	0.3%	13

Nelpa Lifesciences Inc imports 11 pharmaceutical products across 7 categories into Philippines totaling $13.3M.

Nelpa Lifesciences Inc — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Nelpa Lifesciences Inc is a pharmaceutical importer and wholesaler based in the Philippines, specializing in the procurement and distribution of finished pharmaceutical formulations. The company is headquartered in Muntinlupa, Manila, at Unit 305, Venture Building, Madrigal Business Park. Established in 2009, Nelpa Lifesciences Inc has been actively involved in the Philippine pharmaceutical supply chain, focusing on importing a diverse range of pharmaceutical products from international suppliers. The company's operations are guided by its License to Operate (LTO) issued by the Philippine Food and Drug Administration (FDA), which authorizes it to import and distribute pharmaceutical products within the country. (verification.fda.gov.ph)

2Distribution Network

Nelpa Lifesciences Inc's distribution network is strategically designed to ensure efficient delivery of pharmaceutical products across the Philippines. While specific warehouse locations are not publicly disclosed, the company's central office in Muntinlupa serves as a key hub for operations. The company leverages a robust logistics infrastructure to manage the importation and distribution of pharmaceutical products, ensuring timely and reliable delivery to various regions within the country. This logistical capability is crucial for maintaining a steady supply of essential medications to meet the demands of the Philippine healthcare market.

3Industry Role

In the Philippine pharmaceutical supply chain, Nelpa Lifesciences Inc functions primarily as a pharmaceutical importer and wholesaler. The company sources finished pharmaceutical formulations from international suppliers, particularly from India, and distributes these products to various stakeholders within the healthcare sector. By importing a diverse range of pharmaceutical products, Nelpa Lifesciences Inc plays a pivotal role in enhancing the availability and accessibility of essential medications in the Philippines.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Nelpa Lifesciences Inc

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Nelpa Lifesciences Inc exhibits a high degree of sourcing concentration, with a significant portion of its pharmaceutical imports originating from India. The company's total import value from India amounts to $13.3 million USD, encompassing 284 shipments across 11 products in 7 therapeutic categories. This concentration indicates a strategic choice to leverage India's established pharmaceutical manufacturing capabilities, ensuring a consistent supply of quality products. The stability of this sourcing relationship is evidenced by the consistent volume of shipments over the years, reflecting a reliable and ongoing partnership between Nelpa Lifesciences Inc and its Indian suppliers.

2Supply Chain Resilience

Nelpa Lifesciences Inc's supply chain resilience is bolstered by its diversified portfolio of 1,053 unique pharmaceutical formulations sourced from 12 verified Indian suppliers. This diversity mitigates risks associated with dependency on a single supplier or product line. The company's strategic sourcing from multiple suppliers enhances its ability to adapt to potential disruptions in the supply chain, ensuring a continuous flow of pharmaceutical products to meet market demands. Additionally, the company's adherence to regulatory compliance standards, as evidenced by its LTO issued by the Philippine FDA, underscores its commitment to maintaining a robust and resilient supply chain. (verification.fda.gov.ph)

Importing Pharmaceuticals into Philippines — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Philippines

1Regulatory Authority & Framework

The primary regulatory authority overseeing pharmaceutical imports in the Philippines is the Food and Drug Administration (FDA), operating under the Department of Health (DOH). The FDA is responsible for ensuring the safety, efficacy, and quality of pharmaceutical products entering the country. Key legislation governing pharmaceutical imports includes the Food, Drugs, and Devices Act (Republic Act No. 3720), which mandates the registration of all drugs and medicines, and the FDA Act of 2009 (Republic Act No. 9711), which established the FDA's authority and operational framework. The registration pathway for pharmaceutical products involves submitting applications to the FDA, providing comprehensive product information, and undergoing evaluation to obtain marketing authorization. This regulatory framework ensures that imported pharmaceutical products meet the required standards for public health and safety. (respicio.ph)

2Import Licensing & GMP

Import licensing in the Philippines is governed by the FDA, which issues Licenses to Operate (LTO) to entities involved in the importation and distribution of pharmaceutical products. To obtain an LTO, companies must demonstrate compliance with regulatory requirements, including adherence to Good Manufacturing Practice (GMP) standards. The FDA recognizes GMP certificates from reputable authorities, such as the World Health Organization (WHO) and the Pharmaceutical Inspection Co-operation Scheme (PIC/S), facilitating the importation of pharmaceutical products that meet international quality standards. Additionally, wholesale distribution authorization is granted to entities that meet the FDA's criteria, ensuring that imported pharmaceutical products are distributed through channels that uphold quality and safety standards. (respicio.ph)

Nelpa Lifesciences Inc — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Nelpa Lifesciences Inc's product strategy focuses on importing pharmaceutical products across various therapeutic categories, with a significant emphasis on cardiovascular medications, nutritional supplements, and analgesics & antipyretics. This strategic focus aligns with the prevalent health concerns in the Philippines, such as cardiovascular diseases, nutritional deficiencies, and the need for effective pain management solutions. The company's importation of these specific therapeutic areas is driven by market demand and the necessity to provide accessible and effective treatments to the Filipino population. By concentrating on these categories, Nelpa Lifesciences Inc addresses critical healthcare needs and contributes to the overall well-being of the community.

2Sourcing Profile

Nelpa Lifesciences Inc's sourcing strategy is centered on procuring generic pharmaceutical formulations from India, capitalizing on the country's robust pharmaceutical manufacturing sector. The company's preference for generic drugs allows it to offer cost-effective alternatives to branded medications, making essential treatments more accessible to a broader segment of the Philippine population. India's compliance with international quality standards, such as WHO GMP and PIC/S certifications, ensures that the imported formulations meet the required safety and efficacy benchmarks. This sourcing approach enables Nelpa Lifesciences Inc to maintain a diverse and high-quality product portfolio that caters to the varied healthcare needs of the market.

Seller's Guide — How to Become a Supplier to Nelpa Lifesciences Inc

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with Nelpa Lifesciences Inc, particularly in therapeutic areas where the company seeks to expand its product offerings. Identifying gaps in Nelpa Lifesciences Inc's current sourcing, such as specific formulations or dosage forms not yet imported, presents an avenue for Indian exporters to introduce their products. By aligning with the company's strategic focus on high-demand therapeutic categories, new suppliers can establish mutually beneficial partnerships that contribute to the growth and diversification of Nelpa Lifesciences Inc's product portfolio.

2Requirements & Qualifications

Indian exporters aiming to supply Nelpa Lifesciences Inc and the Philippine market must ensure that their pharmaceutical products comply with the regulatory standards set by the Philippine FDA. This includes obtaining GMP certifications from recognized authorities, such as WHO GMP or PIC/S, and ensuring that products are registered with the FDA.

TransData Nexus Research · Industry procurement practicesMar 2026

Frequently Asked Questions — Nelpa Lifesciences Inc

What products does Nelpa Lifesciences Inc import from India?

Nelpa Lifesciences Inc imports 11 pharmaceutical products across 7 categories. Top imports: Losartan ($4.2M), Celecoxib ($3.4M), Potassium ($2.3M), Vitamin ($900.0K), Zinc ($800.0K).

Who supplies pharmaceuticals to Nelpa Lifesciences Inc from India?

Nelpa Lifesciences Inc sources from 12 verified Indian suppliers. The primary supplier is Bdh Healthcare Private Limited (20.8% of imports, $4.7M).

What is Nelpa Lifesciences Inc's total pharmaceutical import value?

Nelpa Lifesciences Inc's total pharmaceutical import value from India is $13.3M, based on 284 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Nelpa Lifesciences Inc focus on?

Nelpa Lifesciences Inc imports across 7 categories. The largest: Cardiovascular (31.2%), Nutritional Supplements (29.3%), Analgesics & Antipyretics (25.5%).

Get Full Nelpa Lifesciences Inc Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.